Moxibustion as Adjuvant Therapy for Preventing Bone Loss in Postmenopausal Women: A Randomized Controlled Trial Protocol

West China Hospital, Sichuan University0 sitesStarted: TBDLast updated: February 20, 2023

Conditions

Trial Snapshot

No summary available.

•1) Eligible participants should conform to diagnostic criteria of osteopenia in the AACE/ACE guidelines [6] and those who meet the following inclusion criteria will be included:
•2) females aged 40 ~ 55 years;
•3) women within 5 years of menopause;
•4) the 10-year probability of hip fracture < 3% and any major osteoporotic fracture < 20% predicted by the fracture risk assessment tool (FRAX);
•5) patients who agree to participate in this study and provide written informed consent.

•1) Patients with osteoporotic fractures;
•2) Patients who have used or are using anti-osteoporosis drugs (such as bisphosphonates, calcitonin, etc.);
•3) Patients who have taken other drugs affecting bone metabolism (such as estrogen, glucocorticoid, etc.) in the last 3 months;
•4) Patients who have abnormal anatomy of the lumbar spine or hip and the BMD cannot be accurately measured by DXA detection;
•5) Patients who have endocrine diseases related to secondary osteoporosis (such as diabetes, hyperthyroidism, hypothyroidism, thyroid cysts, etc.);
•6) Patients suffering from rickets, rheumatoid arthritis and other diseases affecting the balance of bone metabolism;
•7) Patients with hysterectomy or ovariectomy;
•8) Patients with serious heart, liver, kidney and mental diseases;
•9) Patients with drug or alcohol dependence or abuse;
•10) Patients participating in other clinical trials.

Sponsor

West China Hospital, Sichuan University